TTP, a technology and product development firm, has launched Cellular Origins, which was created to address the manufacturing of cell and gene therapies (CGTs) that are in late-stage development. According to the company, Cellular Origins will enable full automation of current CGT manufacturing processes. The platform has been developed for flexibility, with the ability to combine current workflows and existing instrumentation.
Precedence Market research points to the fact that the market has seen significant growth over recent years, but as TTP alluded to, manufacturers have struggled to meet demand for cost-effective, scalable therapy production. As a result, they believe there is an urgent need for solutions that provide large-scale access to more economically priced therapeutics.
“We are really excited to announce the launch of Cellular Origins,” says Matthew Carr, head of life sciences at TTP. “ … We have every confidence that Cellular Origins will deliver on its mission to address the urgent need for scalable, cost-effective, and efficient manufacture of cell and gene therapies, enabling many more patients to benefit from the very latest advances in cell therapy.”
Read more about the introduction here.